Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Metals Lab Opens

Published: Thursday, June 20, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
RSSL has unveiled the latest stage of its recent expansion with the opening of its new metals laboratory, and signing of a laboratory partnership agreement with Agilent.

The new laboratory is bigger and better equipped, meaning that RSSL will be able to provide a more thorough, and more efficient investigative service for the food and drinks industries.

Metals such as arsenic, cadmium, lead and mercury are natural occurring chemical compounds. They can be present at various levels in the environment, and can occur as residues in food because of their presence in the environment, as a result of human activities such as farming, industry or car exhausts or from contamination during food processing and storage.

The basic principles of EU legislation on contaminants in food are contained in Regulation 315/93/EEC, and Regulation EC 1881/2006 lays down maximum levels for certain contaminants in foodstuff, including lead, cadmium, mercury and inorganic tin.

RSSL is now superbly equipped to deal with all the analytical challenges posed by different metals in different matrices.

New equipment has been added to enhance RSSL's current capabilities. This includes ICP-MS (inductively coupled plasma mass-spectrometry), ICP-OES (inductively coupled plasma optical emission spectroscopy), AAS (atomic absorption spectrometry), and MP-AES (microwave plasma-atomic emission spectrometry).

These four complementary technologies give RSSL options to quantify trace metal contamination in all kinds of matrices, with accuracy and efficiency not possible by wet-chemistry methods.

As Agilent's sole partner laboratory in the UK for atomic spectroscopy, RSSL will also be established as the premiere site for developing new techniques and applications for Agilent's technologies, benefiting from Agilent's support and expertise, and offering a demonstration site for Agilent equipment.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!